We're in this from a bit higher. Still holding. We think it's bottoming here. TP 46% from our entry. ~ 56% from here. Would love to swing a weekly SFP today for confirmation, but not really necessary. LTF looks good.
Pfizer Inc. ( NYSE:PFE ) sent shockwaves through the market with a stunning first-quarter performance, catapulting its stock price upward following a robust quarterly beat that surpassed analysts' expectations by a wide margin. The pharmaceutical giant reported adjusted earnings of 82 cents per share, significantly outpacing the forecasted 51 cents per share, and...
Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week...
In a landmark decision, the Food and Drug Administration (FDA) has given its stamp of approval to Pfizer's groundbreaking gene therapy for hemophilia B, marking a pivotal moment in the field of genetic medicine. Hemophilia B, a rare inherited bleeding disorder affecting thousands in the U.S., has long posed significant challenges for patients and caregivers due to...
Despite short-term challenges like revenue and earnings declines in the current quarter, Pfizer (PFE) maintains a positive long-term growth trajectory. With optimistic earnings estimates for the full fiscal year, consistent EPS beats, and a discounted valuation relative to peers, Pfizer represents an attractive investment opportunity. Trade Idea: Buy Pfizer...
Overall Trend: PFIZER, INC (PFE) Downtrend: The price being below the 50, 100, and 200-day moving averages since January 2023 suggests a downtrend. Price Movement: Consolidation: The current price of $25.69 near the 52-week low indicates a possible consolidation phase. Without a one-week chart, it's difficult to say for sure if the price is bouncing off...
Pfizer (PFE): NYSE:PFE At Pfizer, we believe that Wave (2) has not yet completed because Wave B precisely hits the 138% level and structurally does not make sense unless we see a breakthrough of the invalidation zone of the potential subordinate Wave (i) at about $41.62. However, we must form at least a double bottom at $11, which is our minimum expectation...
Reasons for bullish bias: - The price has broken the downtrend trendline - An entry at the lower highs (LH) breakout will provide further confirmation - Currently, the price is in a consolidation phase Here are the recommended trading levels: Entry Level(Buy stop): 30.18 Stop Loss Level: 25.26 Take Profit Level 1: 35.1 Take Profit Level 2: 40.02 Take Profit Level 3: Open
It seems like the price may have hit its bottom, as we're seeing two Key Reversals on the Monthly timeframe. This scenario could signal a Double Bottom, setting the stage for a high-probability trade setup with waiting for the price to break through the recent Lower High (LH) to confirm a change in trend. Shifting our focus to the Daily timeframe, there...
The biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance...
Hello Traders, welcome to today's analysis of Pfizer. -------- Explanation of my video analysis: All the way back in 2012 Pfizer created a massively bullish triangle reversal pattern at the $17.00 level. This was followed by a +200% rally. Since 2022 Pfizer has been dropping significantly and is now retesting the support level which I mentioned in the...
In an unexpected twist, Pfizer ( NYSE:PFE ), the U.S. pharmaceutical giant, has defied market expectations by reporting a surprise quarterly profit. This surprising turnaround can be attributed to the resilient demand for COVID-related products, outperforming the company's own projections. The earnings report for the fourth quarter revealed adjusted earnings of 10...
A viewer on my Livestream Friday brought to my attention that Pfizer NYSE:PFE is coming off a major low (COVID Low) and has done a pullback to the 50% of the Impulse Move off said low. This is why I love doing Livestreams and having a trading community... idea crowdsourcing! I like these setups especially as the S&P 500 and many stocks within it are making new...
The launch of a Bitcoin ETF could have a significant impact on Coinbase, the largest cryptocurrency exchange in the United States. Some analysts believe that the ETF could lead to a decline in trading volume on Coinbase, as investors may choose to trade Bitcoin through the ETF rather than directly on the exchange. Additionally, the ETF could put pressure on...
In a significant stride towards enhancing public health, Health Canada has recently granted approval for Pfizer's groundbreaking bivalent Respiratory Syncytial Virus (RSV) vaccine, ABRYSVO™. This development is a crucial step in safeguarding both older adults and infants through maternal immunization. With the potential to revolutionize preventive healthcare,...
Moderna has had an astronomical rise due to the vaccine. The technical setup looks excellent to the short side. TD9's on the daily, 2 day, 3 day, big divergences on many timeframes. That said - there is headline risk with this - if they get FDA approval it would likely squeeze.
As a double top a lot of thinks in my mind. i will update ...
Pfizer is one of those companies that we all feel has been shady and the stock value shows it. As much as human emotion can draw this value down, hedge funds and smart money will start stepping in now. The chart says it all. We are talking about one of the longest running publically traded companies folks, this will rebound. Its not a matter of if, but when. I...